Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon lambda-1a vs peginterferon alfa-2a with ribavirin and telaprevir in genotype 1 chronic hepatitis C
2011-004695-11Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C virus infection comparing Peginterferon lambda-1a + ribavirin + telaprevir with Peginterferon alfa-2a + ribavirin + telaprevir (2 arms). Started Apr 2013; status: completed.
02
Drugs
peginterferon lambda-1apeginterferon alfa-2aribavirintelaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-004695-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004695-11.